Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor.

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Abstract Text:

CI-1033 (canertinib) is an irreversible inhibitor of the erbB family of transmembrane tyrosine kinase receptors, including the epidermal growth factor (EGF) receptor. Various inhibitors of the EGF receptor, including CI-1033, have resulted in cutaneous toxicity in humans as a common adverse event. In a chronic toxicity study in rats, CI-1033 produced cutaneous lesions with morphologic characteristics similar to that reported in man. Here the authors describe in detail the dermal changes observed, along with other noteworthy findings of that study. Male and female Wistar rats (15/sex/group) were administered CI-1033 for 27 weeks at 2.5, 5, or 10 mg/kg (15, 30, or 60 mg/m(2), respectively) by gavage. Control animals (15/sex) received vehicle alone (aqueous 0.5% methylcellulose) in a dose volume of 5 mL/kg. Six animals/sex/dose were included for toxicokinetic evaluations. Skin lesions were the primary drug-related toxicity and occurred at > or = 2.5 mg/kg in a dose-dependent fashion. The major gross lesions were papules that evolved into crusts and scales that were first observed in weeks 1 and 3, respectively. Alopecia developed in conjunction with the papular eruptions. Skin changes were most pronounced in females, possibly due to higher drug levels. In week 13, CI-1033 plasma AUC(0-24) values were 527 to 1980 ng.h/mL in males and 844 to 2920 ng x h/mL in females at 2.5 to 10 mg/kg. Microscopic changes could be described as 3 patterns that affected the tail and body (haired skin). Pattern 1 consisted of epidermal changes that started as a superficial, perivascular spongiotic dermatitis with evolving epidermal hyperplasia, scale-crusts, and areas of ulceration. Areas of hyperplasia on the tail were often associated with the development of new hair follicles. Pattern 2 was characterized by a suppurative to pyogranulomatous infundibular folliculitis. Pattern 3 consisted of abnormally oriented hair follicles with malformed hair shafts that were associated with a deeper (isthmic) folliculitis; this correlated with alopecia. Elevations in bone marrow myeloid counts correlated with a peripheral leukocytosis, consistent with inflammatory changes in the dermis. In addition, hepatic cholestasis and epithelial atrophy in the gastrointestinal tract and vagina occurred at > or = 2.5 mg/kg. In conclusion, CI-1033 produced cutaneous lesions involving the epidermis and hair follicle, and the morphologic characteristics were similar to that reported in clinical studies with various inhibitors of the EGF receptor. These changes are consistent with pharmacologic inhibition of the EGF receptor in these tissues and demonstrate that the rat can serve as an animal model for investigating the mechanisms for this toxicity.

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Toxicologic pathology

VOLUME: 36

Page Numbers: 410-9

Journal Abbreviation:

ISSN: 1533-1601

DAY: 8

MONTH: 05

YEAR: 2008

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7905907

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor.

AFFILIATION: Drug Safety Research & Development, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA. apbrown07@comcast.net

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Toxicol Pathol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor Related Publications

• Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh.
• Complex organization of human primary motor cortex: a high-resolution FMRI study.
• Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor.
• Dental pulp stem cells: a promising tool for bone regeneration.
• Determinants of arsenic metabolism: blood arsenic metabolites, plasma folate, cobalamin, and homocysteine concentrations in maternal-newborn pairs.
• Developmental impacts of heavy metals and undernutrition.
• Enzyme cytochemistry of cell cultures subjected to the action of Staphylococcus alpha-toxin.
• Folic acid supplementation lowers blood arsenic.
• Four-dimensional spatial reasoning in humans.
• Hypothermia control in elderly surgical patients in the intraoperative period: evaluation of two nursing interventions.
• Integrating technology assessment and medical practice evaluation into hospital operations.
• Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
• Isolation and purification of functional bovine lung mast cells (BLMCs).
• L2 chordoma in an 11-year-old girl.
• Low-temperature sterilization and new technologies.
• Relationship between unconstrained arm movements and single-neuron firing in the macaque motor cortex.
• Simvastatin with or without ezetimibe in familial hypercholesterolemia.
• Water arsenic exposure and intellectual function in 6-year-old children in Araihazar, Bangladesh.
• [Long term functional outcomes after ileoanal pouch in patients with and without postoperative complications]